IGI Laboratories Reports Second ANDA Submission

IGI Laboratories, Inc. IG today announced that it has submitted its second abbreviated new drug application to the US FDA. IGI President and CEO Charlie Moore commented, “We are proud to report that we are executing our strategy of developing and submitting ANDAs. Our experienced team of development professionals is focused on the task of building a portfolio of topical drug products for IGI. We expect to continue this process in 2011.” The development of ANDA products has successfully been integrated into the company's ongoing contract services business.